When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant Sciences's relugolix combo successful in second late-stage endometriosis study
Myovant Sciences Ltd.
Myovant Sciences (MYOV+11.4%) announces results from a second Phase 3 clinical trial evaluating once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis-related pain that were consistent with the first Phase 3.
More news on: Myovant Sciences Ltd., Healthcare stocks news, Stocks on the move,